Through CERP™, over 275 global research
agreements with 235+ independent, expert investigators are
uncovering the full potential of NAD+ by researching ChromaDex’s
Niagen® ingredient, patented nicotinamide riboside (NR), one of the
most studied and efficient modern NAD+ precursors in the healthy
aging space, among other ingredients
On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority
on nicotinamide adenine dinucleotide (NAD+) research and healthy
aging, celebrated the 10th anniversary of its award-winning
ChromaDex External Research Program (CERP™).
Through CERP, independent scientists and investigators from some
of the world’s top research institutions request ChromaDex’s
proprietary Niagen® ingredient (patented nicotinamide riboside or
NR), one of the most studied and efficient modern NAD+ precursors
in the healthy aging space, among other ingredients and placebos.
These investigators are looking to advance research on the health
benefits of increasing NAD+ levels through Niagen supplementation.
Since its founding ten years ago, this unique, industry-leading
program has helped produce the trusted science behind Niagen by
achieving over 270 third-party initiated, independently funded
research agreements with investigators, resulting in over 150
peer-reviewed publications, including 27 peer reviewed clinical
studies, on Niagen.
Some of CERP’s most published investigators include industry
leading researchers such as Dr. Charles Brenner (Alfred E Mann
Family Foundation Chair of Diabetes & Cancer Metabolism at City
of Hope, the discoverer of the vitamin activity of NR, and the
Chief Scientific Advisor of ChromaDex), Dr. Vilhem Bohr (Affiliate
Professor in Genome Instability & Neurodegeneration at the
University of Copenhagen and one of the world’s most published
researchers on aging), Dr. Evandro Fang (Associate Professor at the
University of Oslo, leading an international anti-aging laboratory
at the University of Oslo), among others.
“This marks a milestone moment in the NAD+ industry. On behalf
of the ChromaDex family, we are thrilled to commemorate our
ChromaDex External Research Program as it celebrates a decade of
setting the industry standard for excellence in collaborative
research,” said Rob Fried, the CEO of ChromaDex. “From the day
ChromaDex was formed in 1999, our relationships with leading
universities and scientific institutions have informed our work and
helped us advance research while building the company brick by
brick. The brightest minds in scientific innovation have led us in
an undying pursuit of quality and high standards for Niagen, and
our ChromaDex External Research Program has been essential in
achieving this.”
Because ChromaDex holds scientific integrity to the highest
standards, over 95% of studies conducted via CERP are completely
independent, investigator-initiated and third-party funded. This
approach fosters great trust in the research, as often there is
skepticism around industry-funded research in the dietary
supplement industry. CERP has produced over 70% of registered
ongoing or completed NR trials listed on clinicaltrials.gov using
Niagen, which is a testament to the tremendous value of the
program.
To ChromaDex’s knowledge, this is the only dedicated program
supporting industry researchers, scientists, universities, and
doctors to advance and develop the science behind NAD+ to this
extent in the dietary supplement space. In fact, the program has
proven to be beneficial to all researchers and product developers
in the NAD+ industry, including direct competitors, as research
from the program has demonstrated that NAD+ supplementation
promotes cellular health and may be beneficial to aging and
vulnerable health populations.
“CERP is not only a program that provides research materials,
including bulk and clinical capsules with placebo, but our
uniqueness is also centered upon building and maintaining
relationships with our CERP Investigators,” said Dr. Yasmeen
Nkrumah-Elie, Global Director of External Research for ChromaDex.
“We provide a quarterly newsletter highlighting the researchers and
their publications to promote the scientists as well as to advance
the science. This is why we can confidently state that CERP is
setting the standard for excellence for academic-industry
relationships.”
ChromaDex’s flagship ingredient, Niagen, has been at the
forefront of NAD+ research and healthy aging categories as it is
one of the most studied and efficient NAD+ precursors. The research
conducted by independent investigators through CERP has expanded
the understanding of NR in key health areas including Parkinson’s
disease, Alzheimer’s disease, muscle health, heart failure, among
others. For example:
- Lapatto et al, 2023, a first-of-its kind published and
peer-reviewed clinical study, as reported in the journal Science
Advances by a team of scientists led by Dr. Eija Pirinen
(University of Helsinki and University of Oulu) and Dr. Kirsi
Pietiläinen (University of Helsinki), demonstrated an increase in
mitochondrial biogenesis following NR supplementation via Niagen in
humans.
- Brakedal et al., 2022 is a first-ever clinical study, as
reported in the peer-reviewed journal Cell Metabolism by a team of
scientists led by Prof. Charalampos Tzoulis, Haukeland University
Hospital and University of Bergen, in Norway. The clinical trial
investigated Niagen NR in patients with Parkinson’s disease (PD).
Results of the phase I clinical trial showed that NR
supplementation significantly increased cerebral NAD+ levels,
resulted in altered cerebral energy metabolism and decreased levels
of inflammatory cytokines in patients with PD. Because of the
success of this phase I study, Dr. Tzoulis is leading a phase II
clinical study, which will be the longest CERP study once
completed. The results of this study supports previous research
around the promising effects of NR supplementation for brain
health.
- Wang et al., 2022 as reported in the peer-reviewed journal
JACC: Basic to Translational Science by a team of scientists led by
Dr. Kevin O’Brien, Division of Cardiology, and Dr. Rong Tian,
Mitochondria and Metabolism Center, University of Washington School
of Medicine, Washington, investigated the safety and tolerability
of the Niagen in Stage C heart failure patients with reduced
ejection fraction (HFrEF), which occurs when the left ventricular
ejection fraction (LVEF) is 40% or less. Results demonstrate that
high-dose NR via Niagen was safe and well-tolerated, almost
doubling whole blood NAD+ levels, increasing white blood cell
mitochondrial respiratory function and decreasing the expression of
inflammatory markers building on previous CERP heart studies
demonstrating the positive effects of NR supplementation for heart
health.
“The advantages of CERP include access to high-quality research
materials, unpublished studies and technical advice, and networking
opportunities with other leading researchers in the NAD+ field,”
CERP Investigator Dr. Pirinen commented. “Our findings through CERP
are a great advance in the field of muscle mitochondrial research,
and they encourage us and others to continue to test the impact NR
may have on muscle mitochondrial dysfunction in humans.”
CERP Investigator Dr. Tzoulis remarked, "Our research has
nominated NAD+ replenishment therapy with NR as a potential disease
modulating therapy for Parkinson's disease. NADPARK, the first of
many ongoing NAD+ trials in Parkinson's disease, showed that NR
supplementation significantly increased NAD+ levels in the patient
brain, and resulted in altered cerebral metabolism and decreased
markers of inflammation in the fluid surrounding the brain and
spinal cord. Moreover, the ability to augment brain NAD+ levels
using NR now opens potential new avenues for the treatment of
several neurological diseases. By providing us with NR (Niagen),
the CERP team has made an essential contribution to our studies.
Multiple new phase II trials have been initiated at our Center with
the CERP team’s valuable contribution of the NR and placebo
material required for the studies."
Started in 2013 by Frank Jaksch, ChromaDex Co-Founder and
Executive Chairman, CERP has been pioneering the science of Niagen
and NAD+, among other materials. Today, this unique,
industry-leading program has research agreements with over 200
institutions in 31 countries, representing over $95 million in
estimated total research value. The program has also resulted in a
strong patent portfolio for NR with an impressive array of over 40
granted patents relating to Niagen and other precursors to NAD+
protecting ChromaDex’s future innovations.
For additional information on the science supporting Niagen
visit www.chromadex.com, and to apply for CERP, please visit
https://www.chromadex.com/research/cerp/.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related related to results of the
NIAGEN® studies, their significance and whether the studies show
potential for benefits on human health, aging, and vulnerable
health populations, whether the program is beneficial to all
researchers and product developers in the NAD+ space, including
direct competitors, and whether the research conducted by
independent investigators through CERP has expanded the
understanding of NR in key health areas including Parkinson’s
disease, Alzheimer’s disease, muscle health, heart failure, among
others. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. Risks that contribute to the uncertain nature of these
forward-looking statements include the impact of the COVID-19
pandemic on our business and the global economy; our history of
operating losses and need to obtain additional financing; the
growth and profitability of our product sales; our ability to
maintain sales, marketing and distribution capabilities; changing
consumer perceptions of our products; our reliance on a single or
limited number of third-party suppliers; and the risks and
uncertainties associated with our business and financial condition.
More detailed information about ChromaDex and the risk factors that
may affect the realization of forward-looking statements is set
forth in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230616691883/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ChromaDex (NASDAQ:CDXC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024